Výsledky vyhledávání - "Suzanne Berlin"

Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

Autor: Michael J. Birrer, Rebecca C. Arend, McKenzie E. Foxall, Hannah M. Beer, Jaclyn A. Wall, Susana M. Campos, Suzanne Berlin, Yael C Cohen, Tamar Rachmilewitz Minei, Richard T. Penson, Dror Harats

Publikováno v: Gynecologic Oncology. 157:578-584

Objective Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45936967b82485c6ebc8bc4a29520c75
https://doi.org/10.1016/j.ygyno.2020.02.034

Zobrazit plný text záznamu

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors

Autor: Susana Campos, Ursula Matulonis, Suzanne Berlin, Neil Horowitz, Joyce Liu, Carolyn Krasner, Lee Hang, Corrine Zarwan, William Barry, Tina Colella, Christen Whalen, Melina Shoni, Christine Lundquist, Michael J. Birrer, Richard Penson

Publikováno v: International journal of clinical oncology. 27(12)

The combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with newly diagnosed Mullerian tumors, we investigated the progression-free survival benefit of bevacizumab and bevacizu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9fd6521288d6d1e6bd7e6162618271
https://pubmed.ncbi.nlm.nih.gov/36344654

Zobrazit plný text záznamu

A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies

Autor: Susana M. Campos, Suzanne Berlin, Carolyn N. Krasner, Christin Whalen, Tina Atkinson, Kristin Meegan, Lauren Pereira, Karin Tyburski, Weixiu Lou, Hang Lee, Neil Horowitz, Richard T. Penson

Publikováno v: Cancer chemotherapy and pharmacology. 89(3)

Temsirolimus, a mTOR inhibitor, and AZD2171, a VEGFR inhibitor, have independently shown activity in patients with gynecological malignancies. Understanding the pivotal role of the PI3K/PTEN/AKT/mTOR pathway in regulating angiogenesis, a phase I stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::857e5ee32f54cfb6ff73892147ab078d
https://pubmed.ncbi.nlm.nih.gov/35142863

Zobrazit plný text záznamu

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Publikováno v: Annals of Oncology, 27(11), 2124. Oxford University Press

Background MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody–drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac59c52b04eec424c73cc3e1e5cb370
https://doi.org/10.1093/annonc/mdw401

Zobrazit plný text záznamu

Molecular Characterization of an Endometrial Endometrioid Adenocarcinoma Metastatic to a Thyroid Hürthle Cell Adenoma Showing Cancerization of Follicles

Autor: William C. Faquin, Emily E. Meserve, Vânia Nosé, A. Afrogheh, Suzanne Berlin, Antonia E. Stephen, Peter M. Sadow

Publikováno v: Endocrine Pathology. 27:213-219

Tumor-to-tumor metastasis is rare. Herein, we present a unique case of endometrial endometrioid adenocarcinoma metastatic to a thyroid Hürthle cell adenoma 9 years after initial diagnosis. On histologic examination of the thyroid, the malignant endo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceb304f47182b223a90a1a1afe0540f
https://doi.org/10.1007/s12022-015-9412-5

Zobrazit plný text záznamu

A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer

Autor: Suzanne Berlin, Ursula A. Matulonis, Neil S. Horowitz, Cheryl A. Sadow, Michael G. Muto, Ross S. Berkowitz, Colleen M. Feltmate, Hang Lee, S. M. Campos, Akila N. Viswanathan

Publikováno v: Gynecologic Oncology. 132:55-60

Objectives To determine the toxicity and survival rates in a trial of concurrent bevacizumab and external beam radiation (EB) for patients with recurrent endometrial or ovarian cancer. Methods Nineteen women with recurrent endometrial ( n =15) or ova

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe0756653373ca9a45d31f4c79a6d4b
https://doi.org/10.1016/j.ygyno.2013.10.031

Zobrazit plný text záznamu

Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: with an immunotherapeutic effect

Autor: Michael J. Birrer, Suzanne Berlin, Dror Harats, Susana M. Campos, Richard T. Penson, Tamar Rachmilewitz Minei, Yael C Cohen

Publikováno v: Journal of Clinical Oncology. 37:5542-5542

5542 Background: VB-111 is a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response. We report final results of a phase I/II study of VB-111 in combination

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8371a25555c4e755c0b9912156551f95
https://doi.org/10.1200/jco.2019.37.15_suppl.5542

Zobrazit plný text záznamu

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

Autor: Maria Roche, Christin Whalen, Suzanne Berlin, Jackie Szymonifka, Karin Tyburski, Ursula A. Matulonis, L. Pereira, Neil S. Horowitz, Susana M. Campos, Richard T. Penson

Publikováno v: Gynecologic Oncology. 128:215-220

Objective Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research. The tyrosine kinase receptor inhibitors target several receptors allowing for the pharmacological disruption of several independent pathways. Sunitinib mal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cd3928ee9ef0f5d7db238d090f7353a
https://doi.org/10.1016/j.ygyno.2012.07.126

Zobrazit plný text záznamu

Young Women Diagnosed with Early-Stage Ovarian Cancer or Borderline Malignancy of the Ovary: A Focus on Fertility and Sexual Function

Autor: Merily M Mosquera, Neil S. Horowitz, Suzanne Berlin, Ursula A. Matulonis, L. Pereira, Susana M. Campos, Michael G. Muto

Publikováno v: Journal of Psychosocial Oncology. 30:387-401

Malignant ovarian neoplasms represent the leading cause of death in gynecological malignancies. Although the majority of ovarian neoplasms occur in women of advanced years, ovarian neoplasms can occur in women of the reproductive age group. Preservat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a94883524cfd42589a93cb14570a00
https://doi.org/10.1080/07347332.2012.684854

Zobrazit plný text záznamu

Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer

Autor: T. Atkinson, Joyce F. Liu, Ursula A. Matulonis, Julie Lee, Margaret Hill, Christin Whalen, Suzanne Berlin, Susana M. Campos, L. Pereira, Hang Lee

Publikováno v: Gynecologic Oncology. 126:41-46

Objective Test the safety and efficacy of sequentially blocking angiogenesis by adding oral cyclophosphamide to bevacizumab following cancer progression on bevacizumab in patients with recurrent ovarian cancer. Methods Eligibility included ≤2 lines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a6f01d760f1ba3163246a36821c02a0
https://doi.org/10.1016/j.ygyno.2012.04.003

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání